AstraZeneca says FARXIGA reduced major adverse cardiovascular events by 16%.
Results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA reduced the relative risk of major adverse cardiovascular events by 16% compared to placebo in patients with type 2 diabetes who had a prior heart attack. In another pre-specified sub-analysis, FARXIGA compared to placebo reduced the relative risk of hospitalization for heart failure in patients with T2D regardless of their ejection fraction status, a measurement of the percentage of blood leaving the heart with each contraction. FARXIGA reduced hospitalization for heart failure by 36% in patients with HF reduced ejection fraction and by 24% in patients without HFrEF.These pre-specified sub-analyses of DECLARE-TIMI 58 add to the primary results of the trial presented in November 2018, which showed that FARXIGA reduced the risk of the composite of hHF or CV death compared to placebo, consistently across the trial's entire patient population. Additionally, there were fewer major adverse cardiovascular events observed with FARXIGA in the broad patient population, however this did not reach statistical significance. FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FARXIGA is not indicated to reduce the risk of CV events, HF, or death.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 18, 2019|
|Previous Article:||BioScrip outlook positive following 'unexpected' merger, say Lake Street.|
|Next Article:||Esperion presents Phase 3 results from Study 2 of bempedoic acid at ACC.|